MW 291.77 Da, Purity >98%. Selective D1 receptor partial agonist. Active enantiomer of (±)-SKF-38393 (ab120740).
15-PGDH, 15-hydroxyprostaglandin dehydrogenase [NAD+], 3',5'-cyclic AMP synthetase, 70 kDa lysosomal alpha-glucosidase, A3G, ABC3G_HUMAN, AC-III, AC2, AC6, ACVI, ADCY3_HUMAN, ADCY6_HUMAN, ADCYB, APOBEC-related cytidine deaminase, APOBEC-related protein, APOBEC-related protein 9, APOBEC3G, ARCD, ARP-9, ATP pyrophosphate lyase 2, ATP pyrophosphate-lyase, ATP pyrophosphate-lyase 3, ATP pyrophosphate-lyase 6, ATP pyrophosphate-lyase 8, Acid Maltase, Acid alpha glucosidase, Adenylate cyclase, Adenylate cyclase 2, Adenylate cyclase 2 (brain), Adenylate cyclase 6, Adenylate cyclase 8, Adenylate cyclase II, Adenylate cyclase type 2, Adenylate cyclase type 3, Adenylate cyclase type 6, Adenylate cyclase type II, Adenylate cyclase type III, Adenylate cyclase type VI, Adenylate cyclase type VIII, Adenylyl cyclase 3, Adenylyl cyclase 6, Adenylyl cyclase 8 brain, Aglucosidase Alfa, Alpha-glucosidase, Apolipoprotein B editing enzyme catalytic polypeptide like 3G, Apolipoprotein B mRNA editing enzyme catalytic polypeptide 3G, Apolipoprotein B mRNA editing enzyme catalytic polypeptide like 3G, Apolipoprotein B mRNA editing enzyme catalytic subunit 3G, Brain adenylate cyclase 8, CEM-15, Ca(2+)-inhibitable adenylyl cyclase, Ca(2+)/calmodulin-activated adenylyl cyclase, D(1A) dopamine receptor, D(1B) dopamine receptor, D(2) dopamine receptor, D(3) dopamine receptor, D(5) dopamine receptor, D1 beta dopamine receptor, D1A dopamine receptor, D1B dopamine receptor, D2 dopamine receptor, D2DR, D2R, D5 dopamine receptor, DADR, DBDR, DKFZp779F075, DNA dC dU editing enzyme APOBEC 3G, DNA dC->dU editing enzyme, DNA dC->dU-editing enzyme APOBEC-3G, DNA replication inhibitor, DRD 1A, DRD 1B, DRD1L2, DRD1_HUMAN, DRD2_HUMAN, DRD5_HUMAN, Dopamine D1 receptor, Dopamine D2 receptor, Dopamine D3 receptor, Dopamine D5 receptor, Dopamine receptor D1B, Dopamine receptor D2, EC 3.5.4.-, EC 4.6.1.1, FLJ12740, FLJ16822, FLJ45092, GEMI_HUMAN, GMNN, Geminin, Geminin DNA replication inhibitor, Glucosidase alpha, Glucosidase alpha acid, Glucosidase alpha acid (Pompe disease glycogen storage disease type II), HBAC1, HBAC2, Hpgd, Hydroxyprostaglandin dehydrogenase 15 (NAD), KIAA0422, KIAA1060, LYAG_HUMAN, Lysosomal Alpha-Glucosidase, MDS019, MGC10601, MGC133314, NAD+ dependent 15 hydroxyprostaglandin dehydrogenase, OTTHUMP00000028911, OTTHUMP00000039393, OTTHUMP00000218960, OTTHUMP00000219016, OTTHUMP00000219018, PGDH1, PGDH_HUMAN, PHOAR1, Particulate Guanylate Cyclase E, Prostaglandin dehydrogenase 1, RP3 369A17.3, SDR36C1, Short chain dehydrogenase/reductase family 36C member 1, Type II adenylate cyclase, adenylate cyclase 3, apolipoprotein B mRNA editing enzyme cytidine deaminase, apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like, bK150C2.7, dJ494G10.1, deoxycytidine deaminase, dopamine receptor D1, dopamine receptor D5, olfactive type, phorbolin-like protein, phorbolin-like protein MDS019
MW 291.77 Da, Purity >98%. Selective D1 receptor partial agonist. Active enantiomer of (±)-SKF-38393 (ab120740).
Soluble in water to 100 mM.
Selective D1 receptor partial agonist. Active enantiomer of (±)-SKF-38393 (ab120740).
Geminin also known in some contexts as Gmnn is a protein critical in cell cycle regulation and DNA replication. It has a molecular mass of about 25 kDa. Geminin predominantly localizes in the nucleus where it interacts with and inhibits the replication licensing factor Cdt1 preventing re-replication. Dopamine receptors such as DRD1 and DRD2 are important components of the dopaminergic signaling pathways in the central nervous system where they act by binding dopamine and triggering intracellular effects. Likewise Adenylate Cyclases like AC3 AC6 and AC8 are enzymes that convert ATP to cyclic AMP a secondary messenger in various signaling pathways. APOBEC3G also known as A3G functions as a cytidine deaminase involved in the innate immune response and its expression occurs mainly in leukocytes. 15-PGDH is an enzyme important for the metabolism of prostaglandins with significant expression in the liver and kidneys.
These proteins fulfill essential roles in their respective systems. Geminin prevents premature DNA replication by forming part of a regulatory complex with Cdt1. Dopamine receptors like D1 D2 and D5 modulate neurotransmission and play roles in mood reward and motor function interacting with G-protein coupled receptor signaling complexes. Adenylate cyclases regulate the cAMP levels influencing numerous biological processes like hormonal signaling. APOBEC3G impacts viral replication processes particularly in retroviruses by deaminating cytidine to uridine in viral DNA. 15-PGDH controls prostaglandin levels which affect inflammatory responses.
These proteins integrate into important cellular and neurological circuits. Geminin's role in inhibiting Cdt1 is potent in the cell cycle and replication licensing pathway ensuring DNA replication fidelity. Dopamine receptors such as D1 and D2 are important components of the dopaminergic signaling pathways which include interactions with proteins like CAMP-dependent protein kinase (PKA) that translate dopamine binding into cellular responses. Adenylate cyclases such as AC3 and AC8 play roles in the cAMP signaling pathway impacting cellular metabolism. APOBEC3G is linked to antiviral pathways often interacting with proteins involved in restricting viral replication.
These proteins associate with various conditions. Geminin dysregulation often leads to aberrant cell cycle progression which can contribute to cancer development. Dopamine receptors are implicated in neurological and psychiatric disorders; disruptions in D1 and D2 receptor functions link to conditions like schizophrenia and Parkinson’s disease showing connections with proteins such as G-proteins that mediate their signaling. Alterations in adenylate cyclase activity can contribute to metabolic disorders. APOBEC3G impacts HIV-1 pathogenesis by affecting viral replication dynamics. 15-PGDH's role in prostaglandin metabolism links it to inflammatory diseases and cancer as abnormal prostaglandin levels can promote tumor progression.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2D chemical structure image of ab120619, (R)-(+)-SKF38393 hydrochloride, D1 partial agonist
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com